Cholinergic refers to anything in the body that involves acetylcholine, one of the most widespread chemical messengers in the nervous system. If a neuron releases acetylcholine, it is a cholinergic neuron. If a receptor responds to acetylcholine, it is a cholinergic receptor. If a drug mimics or blocks acetylcholine’s effects, it is a cholinergic or anticholinergic drug. The term shows up across fields from neurology and cardiology to dermatology and toxicology because acetylcholine does not just relay messages between nerves and muscles; it also regulates heart rate, digestion, memory, inflammation, and even skin cell behavior. Understanding the cholinergic system helps make sense of conditions as different as Alzheimer’s disease, myasthenia gravis, and nerve agent poisoning.
How Acetylcholine Is Made and Broken Down
Acetylcholine is assembled from two ingredients: choline, a nutrient you get from food, and an acetyl group donated by a molecule involved in energy metabolism. An enzyme called choline acetyltransferase (ChAT) stitches these two pieces together inside nerve terminals.1PubMed Central. Enzymes of acetylcholine metabolism in the rat inferior colliculus Once released into the gap between cells, acetylcholine acts almost instantly on nearby receptors. Its lifespan is extremely short because a second enzyme, acetylcholinesterase (AChE), breaks it apart within milliseconds. The choline fragment is then recycled back into the nerve terminal for another round of synthesis. This rapid build-break-recycle loop is what allows cholinergic signaling to be so precise: muscles can contract and relax dozens of times per second, and brain circuits can fire in tight, well-timed patterns.
Getting choline into the brain in the first place requires dedicated transporter proteins at the blood-brain barrier. Research has identified two key transporters, CTL1 and CTL2, whose activity essentially sets a speed limit on how much acetylcholine the brain can produce.2PubMed Central. Functional Expression of Choline Transporters in the Blood-Brain Barrier This is one reason dietary choline intake matters, and why choline is now recognized as an essential nutrient. Eggs, liver, soybeans, and cruciferous vegetables are among the richest food sources.
Two Families of Receptors
Acetylcholine does not have a single receptor. It has two broad families, named after the substances scientists originally used to distinguish them: nicotine and muscarine.
Nicotinic acetylcholine receptors are ion channels. When acetylcholine binds, the channel opens and allows charged particles to flow through the cell membrane, which can trigger a nerve impulse or a muscle contraction in a matter of milliseconds. These receptors sit at the junction between motor nerves and skeletal muscles, in autonomic ganglia, and throughout the brain. Structural work has mapped the human α7 nicotinic receptor in resting, activated, and desensitized states, revealing how the channel physically opens and then shuts itself off when stimulation is prolonged.3PubMed Central. Structure and gating mechanism of the α7 nicotinic acetylcholine receptor That desensitization step turns out to be important for understanding nicotine addiction, as we will see later.
Muscarinic acetylcholine receptors work differently. Instead of forming channels, they activate internal signaling cascades through intermediary proteins called G proteins. The effects are slower but longer lasting. There are five muscarinic subtypes (M1 through M5), and they can either excite or inhibit the cells they sit on depending on which G protein they couple to. M1 receptors, for example, tend to excite neurons in the brain, while M2 receptors slow heart rate by opening potassium channels in cardiac cells.4PubMed. Cellular signaling mechanisms for muscarinic acetylcholine receptors This dual nature explains why drugs that broadly block muscarinic receptors produce such a grab bag of side effects: dry mouth, blurred vision, constipation, fast heart rate, and confusion all at once.
Cholinergic Signaling in the Body
The most familiar job of acetylcholine is triggering muscle movement. At the neuromuscular junction, the point where a motor nerve meets a skeletal muscle fiber, incoming nerve impulses cause acetylcholine to flood across a narrow gap. It binds nicotinic receptors packed densely on the muscle surface, and the muscle contracts.5PubMed. Molecular architecture of the neuromuscular junction Every voluntary movement you make, from typing to running, depends on this handoff working reliably millions of times a day.
Beyond voluntary muscles, acetylcholine is the main transmitter of the parasympathetic nervous system, the branch of the autonomic nervous system often described as “rest and digest.”6International Review of Movement Disorders. Autonomic nervous system—Anatomy, physiology, biochemistry Parasympathetic nerves use acetylcholine to slow the heart, stimulate digestive secretions, constrict the pupils, and promote urination. The sympathetic (“fight or flight”) system, by contrast, mainly uses norepinephrine at its target organs, though even sympathetic ganglia rely on acetylcholine for internal relay. Sweat glands are a quirky exception: they receive sympathetic innervation but respond to acetylcholine rather than norepinephrine, which is why certain cholinergic drugs can cause excessive sweating.
The Cholinergic Brain
In the central nervous system, clusters of cholinergic neurons in the basal forebrain send long projections throughout the cortex and hippocampus. These projections are far more organized than researchers once assumed. Recent mapping studies show that basal forebrain cholinergic neurons are arranged with real topographical specificity, and their activity patterns help bind together different aspects of cognition, from attention and working memory to the formation of new memories.7PubMed Central. Basal forebrain cholinergic signalling: development, connectivity and roles in cognition
Cholinergic neurons in the brainstem also help regulate sleep. During REM sleep, cholinergic neurons are at their most active while other neurotransmitter groups (particularly those using norepinephrine and serotonin) quiet down.8PubMed. Cholinergic modulation of respiratory brain-stem neurons and its function in sleep-wake state determination This reciprocal seesaw between cholinergic and aminergic systems is thought to control the cycling between sleep stages.
In the striatum, a brain region critical for movement and habit learning, cholinergic interneurons act as local regulators. Despite being few in number, these cells exert outsized influence. They can control the release of dopamine from nearby nerve terminals by activating nicotinic receptors on dopamine-releasing axons.9PubMed Central. Cortical Control of Striatal Dopamine Transmission via Striatal Cholinergic Interneurons This acetylcholine-dopamine crosstalk is central to how the brain selects actions and learns from rewards, and its disruption has been linked to movement disorders like Parkinson’s disease.10PubMed Central. Striatal Cholinergic Interneurons: How to Elucidate Their Function in Health and Disease
Alzheimer’s Disease and the Cholinergic Hypothesis
The loss of cholinergic neurons is one of the hallmarks of Alzheimer’s disease. The “cholinergic hypothesis,” proposed decades ago, holds that the progressive death of cholinergic neurons in the basal forebrain drives much of the cognitive decline seen in the disease. Neurofibrillary tangles accumulating in these neurons are thought to be the primary cause of their dysfunction and death, leading to a widespread loss of cholinergic connections across the cortex.11Brain. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease Beyond that direct loss, abnormal changes in cholinergic signaling can also promote abnormal phosphorylation of tau protein, inflammation, and cell death, although exactly how these processes interact remains unclear.12PubMed Central. Role of Cholinergic Signaling in Alzheimer’s Disease
The picture has gotten more complicated in recent years. Newer research using animal models of Alzheimer’s disease and Down syndrome suggests that the relationship between acetylcholine and memory is not simply “more is better.” In early stages of the disease, cholinergic activity may actually be excessively high, and that hyperactivity itself contributes to cognitive problems. Only later, as cholinergic neurons degenerate, does the classical deficit set in.13PubMed Central. The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer’s and Down syndrome model systems If this pattern holds in humans, it could explain why cholinesterase inhibitor drugs sometimes seem to help less than expected, or why timing of treatment matters.
Drugs That Boost Cholinergic Signaling
The most widely prescribed Alzheimer’s medications, donepezil, galantamine, and rivastigmine, all work by blocking the enzyme that breaks down acetylcholine. The logic is straightforward: if the brain is losing cholinergic neurons, making the remaining acetylcholine last longer at the synapse should partially compensate. A systematic review and meta-analysis found that all three drugs produced statistically significant improvements in cognitive test scores compared to placebo.14PubMed. Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer’s disease: A systematic review and meta-analysis However, the overall benefit is modest and may not always be noticeable in daily life.15PubMed. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease Among the three, donepezil has been the most thoroughly studied and shows a responder rate (the percentage of patients who show measurable improvement) in the range of about 40 to 58 percent.16PubMed Central. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
These drugs remain the standard pharmacological treatment while researchers pursue more effective approaches. They do not stop the disease from progressing; they slow cognitive decline temporarily and, to a lesser extent, may delay the need for full-time care. Side effects, mostly gastrointestinal (nausea, diarrhea, appetite loss), reflect the fact that boosting acetylcholine activity affects the gut as well as the brain.
Anticholinergic Drugs and Dementia Risk
If drugs that enhance cholinergic signaling can modestly help cognition, what about drugs that block it? Many common medications have anticholinergic effects, meaning they interfere with acetylcholine’s action at muscarinic receptors. The list includes certain antihistamines (like diphenhydramine), bladder medications for overactive bladder, older antidepressants (tricyclics), some antipsychotics, and anti-nausea drugs. Anyone who has experienced drowsiness, dry mouth, or mental fog from an allergy pill has felt anticholinergic side effects firsthand.
Large observational studies have raised concern that heavy, long-term use of strong anticholinergic drugs may increase the risk of developing dementia. A study tracking over 3,400 older adults for an average of about seven years found that those with the highest cumulative exposure to strong anticholinergics (more than three years of daily use) had roughly a 54 percent higher risk of dementia compared to non-users.17PubMed Central. Cumulative Use of Strong Anticholinergic Medications and Incident Dementia A larger nested case-control study using records from over 280,000 people found a similar pattern, with the highest exposure group showing about a 49 percent increase in dementia risk. The risk was particularly pronounced for anticholinergic antidepressants, bladder drugs, antipsychotics, and antiparkinson medications.18JAMA Internal Medicine. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study A third large study confirmed the association and found that increased dementia risk was detectable even when looking at drug exposure 15 to 20 years before diagnosis.19BMJ. Anticholinergic drugs and risk of dementia: case-control study
These are observational findings, not proof of causation. People taking anticholinergic drugs may have underlying conditions (depression, chronic pain, sleep disorders) that themselves raise dementia risk. Still, the consistency across studies, the dose-response relationship, and the biological plausibility (acetylcholine is critical for memory circuits) have led many geriatricians to recommend minimizing anticholinergic burden in older adults when alternatives exist.
When the Immune System Attacks Cholinergic Receptors
Myasthenia gravis is the most well-known autoimmune disease of the cholinergic system. In this condition, the immune system produces antibodies that target nicotinic acetylcholine receptors at the neuromuscular junction. A study of serum from myasthenia gravis patients found that immunoglobulin from about 91 percent of those tested accelerated the degradation of acetylcholine receptors, and immunoglobulin from about 88 percent produced direct blockade of the receptors. In both cases, the severity of these antibody effects closely correlated with how disabled the patient was clinically.20PubMed. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis The result is fluctuating muscle weakness, often starting in the eye muscles (causing droopy eyelids and double vision) and sometimes progressing to difficulty swallowing and breathing. Treatment often involves cholinesterase inhibitors (the same class of drugs used in Alzheimer’s, but at different doses) to boost acetylcholine levels at whatever receptors remain functional, along with immunosuppressive therapies to reduce antibody production.
The Cholinergic Anti-Inflammatory Pathway
One of the more surprising discoveries about the cholinergic system is that it helps regulate inflammation. The vagus nerve, the longest cranial nerve, sends cholinergic signals to immune cells in the spleen and other organs. When acetylcholine released by vagal terminals acts on α7 nicotinic receptors expressed on macrophages and other immune cells, it dials down the production of inflammatory molecules like TNF.21PubMed Central. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation
Animal experiments have shown how consequential this pathway is. Mice lacking the α7 nicotinic receptor subunit or with severed vagus nerves mount an exaggerated, runaway inflammatory response when exposed to bacterial toxins. Stimulating the vagus nerve in normal mice significantly suppresses cytokine release, but that suppression fails completely in the α7 knockouts.22JCI Insight. Physiology and immunology of the cholinergic antiinflammatory pathway Researchers have described the vagus nerve’s role here as a “governor on an engine,” continuously limiting how far the immune response can go. This discovery has prompted clinical trials of vagus nerve stimulation devices for inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease, though those applications are still being evaluated.
Nerve Agents and Pesticide Poisoning
Organophosphate compounds, which include certain pesticides and the nerve agents sarin and VX, are lethal precisely because they exploit the cholinergic system. Their primary mechanism is irreversible inhibition of acetylcholinesterase, the enzyme that normally clears acetylcholine from synapses.23PubMed Central. Mechanisms of Organophosphate Toxicity and the Role of Acetylcholinesterase Inhibition When the enzyme is knocked out, acetylcholine accumulates unchecked. Nicotinic receptors on muscles become overstimulated, producing twitching and then paralysis. Muscarinic receptors in glands and smooth muscle trigger profuse salivation, tearing, urination, diarrhea, and constriction of the airways. In the brain, the flood of acetylcholine overstimulates other neurotransmitter systems and can produce seizures.24PubMed. Neurotoxicity evoked by organophosphates and available countermeasures Without rapid treatment, including atropine (a muscarinic blocker) and pralidoxime (which can reactivate some inhibited enzyme), either the cholinergic crisis or the resulting seizures can be fatal.
Botulinum toxin acts on the opposite end of the same system. Rather than causing too much acetylcholine, it prevents acetylcholine from being released at all. All serotypes of botulinum toxin block the molecular machinery that nerve terminals use to release acetylcholine into the synapse, causing localized muscle paralysis.25PubMed Central. Botulinum toxin In tiny, carefully placed doses, this same mechanism is harnessed therapeutically for conditions ranging from muscle spasticity and chronic migraine to excessive sweating and cosmetic wrinkle reduction. In large uncontrolled doses (botulism), the paralysis can spread to respiratory muscles and become life-threatening.
Nicotine and the Cholinergic System
Nicotine is, chemically, a cholinergic agonist: it activates nicotinic acetylcholine receptors. It crosses the blood-brain barrier easily and stimulates receptors in reward-related circuits, which is why it feels pleasurable and why quitting is hard. But chronic nicotine exposure triggers a paradoxical adaptation. The brain upregulates, or increases the number of, certain nicotinic receptor subtypes, while at the same time many of those receptors become desensitized and less responsive.26PubMed Central. Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction The result is that a smoker’s brain has more nicotinic receptors than a non-smoker’s, but needs nicotine just to bring receptor activity back to a baseline level. When nicotine is withdrawn, all those extra, now-unoccupied receptors contribute to irritability, difficulty concentrating, and cravings.
This receptor-level adaptation also explains why nicotine replacement therapies (patches, gum, lozenges) and partial agonist drugs like varenicline can help with cessation: they provide just enough receptor activation to ease withdrawal without delivering the sharp spike that reinforces the habit.
Acetylcholine Beyond Nerves
One of the more counterintuitive findings in cholinergic biology is that acetylcholine is not exclusively a neurotransmitter. Cells with no connection to the nervous system, including epithelial cells, endothelial cells lining blood vessels, immune cells, and even embryonic stem cells, can synthesize and respond to acetylcholine on their own.27PubMed Central. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans In the skin alone, acetylcholine produced locally by keratinocytes and immune cells is involved in cell proliferation, wound healing, pigment production, sweat and oil gland activity, and blood flow.28PubMed. The non-neuronal cholinergic system of human skin
This “non-neuronal cholinergic system” likely predates the nervous system itself. Evolutionary studies suggest that acetylcholine-based signaling was present before the split between cnidarians (jellyfish, corals) and bilaterians (most other animals), and that its role in muscle contraction evolved later, during bilaterian evolution.29bioRxiv. The origin and evolution of acetylcholine signaling through AchRs in metazoans Acetylcholine may have started out as a general-purpose cell-to-cell signal and only later got recruited by dedicated neurons to become the fast, precise neurotransmitter we know today.
Why “Anticholinergic Burden” Matters as You Age
Many people, especially older adults managing multiple chronic conditions, end up taking several medications that each have mild anticholinergic effects. Individually, a single antihistamine or a low-dose bladder medication may not cause noticeable cognitive problems. But the effects stack. Clinicians now use tools like the Anticholinergic Cognitive Burden (ACB) scale to add up the total anticholinergic load across a patient’s entire medication list. The observational data consistently show that higher cumulative burden is associated with worse cognitive outcomes, and this association appears to hold even when the exposure occurred many years before dementia diagnosis.30BMJ. Anticholinergic drugs and risk of dementia: case-control study
Practical steps worth discussing with a doctor include reviewing all current medications (including over-the-counter ones) for anticholinergic properties, switching to alternatives where they exist (for example, loratadine instead of diphenhydramine for allergies, since loratadine has minimal anticholinergic activity), and deprescribing medications that may no longer be needed. None of this should be done without medical guidance, since some anticholinergic medications treat serious conditions and stopping abruptly can be harmful. But the evidence is strong enough that many geriatric medicine guidelines now flag high anticholinergic burden as a modifiable risk factor worth addressing.